DS-2243a in advanced solid tumors incl. synovial sarcoma or myxoid/round cell liposarcoma
First-in-human trial of DS-2243a in participants with advanced solid tumors
| Agents: | DS-2243a |
| Phase | I |
| Status | Open, recruiting |
| Sponsor | Daiichi Sankyo |
Further information: https://clinicaltrials.gov/study/NCT06644755
This study evaluates safety, tolerability, and efficacy of DS-2243a as a treatment for participants with advanced solid tumors incl. synovial sarcoma and myxoid/round cell liposarcoma.
WHO is the trial for? |
|
WHAT is the key question that this trial is attempting to answer? |
The trial tries to find out the optimal dose of the investigational drug (part 1 of the trial) and will assess whether the drug is safe and how well it works in attacking synovial sarcoma or MRCLS cancer cells (part 2).
The investigational drug is called DS-2243a. |
WHY patients might want to participate? |
This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here. |
WHEN will the trial be open? |
The study is open (recruiting) for participation. |
WHERE is the trial available? |
The trial is currently available in the US. For further information please check here: https://clinicaltrials.gov/study/NCT06644755 |
STUDY DESIGN: What does the study look like? |
This study tests a new drug, DS-2243a, in people with certain cancers incl. specific subtypes of sarcoma to find the safest and most effective dose.
In the first part, participants receive increasing doses to figure out the best amount. In the second part, this dose is given to people with advanced/metastatic synovial sarcoma or myxoid/round cell liposaroma (or other cancers). The study checks for side effects, how well the drug works to shrink tumors, and how long it controls the disease. It also tracks survival rates and how the body processes the drug over time. |
HOW do I get more information? |
Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organisation in your country, please email us for more information: info@sarcoma-patients.org |
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.